Price Chart

Profile

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
URL https://www.kodiak.com
Investor Relations URL https://ir.kodiak.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 28, 2025 (est.)
Last Earnings Release Nov. 14, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
URL https://www.kodiak.com
Investor Relations URL https://ir.kodiak.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 28, 2025 (est.)
Last Earnings Release Nov. 14, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A